Cefiderocol utilization in lung transplant recipients at a single center.

IF 2.6 4区医学 Q3 IMMUNOLOGY Transplant Infectious Disease Pub Date : 2024-08-01 Epub Date: 2024-06-17 DOI:10.1111/tid.14319

Purnadeo N Persaud, Xhilda Xhemali, Kristen Neuhaus, Marie Budev, Jessica Lum

{"title":"Cefiderocol utilization in lung transplant recipients at a single center.","authors":"Purnadeo N Persaud, Xhilda Xhemali, Kristen Neuhaus, Marie Budev, Jessica Lum","doi":"10.1111/tid.14319","DOIUrl":null,"url":null,"abstract":"Background: Multidrug-resistant organisms are increasing and are a significant cause of mortality among lung transplant recipients (LTRs). To assist with this issue, novel pharmacotherapies are being developed. This study describes the utilization of a novel antibiotic, cefiderocol (FDC), in LTRs where limited data exists in the current literature. We primarily assessed the clinical indications, duration of therapy, resistance, and adverse effects.Methods: Conducted as a single-center retrospective review, this study included adult LTRs who received FDC for at least 24 h. Data, extracted from electronic medical records, encompassed patient demographics, transplant history, antimicrobial dosing, adverse effects, bacterial cultures, and outcomes. The research protocol received institutional review board approval.Results: FDC exhibited effectiveness against multidrug-resistant Pseudomonas aeruginosa, with 26% 30-day mortality and microbiological clearance observed in nine out of 13 cases. Notably, FDC was used in diverse clinical settings, including for prophylaxis, empiric, and targeted treatment.Conclusion: Further studies are needed to evaluate optimal clinical indications for FDC use in LTRs.","PeriodicalId":23318,"journal":{"name":"Transplant Infectious Disease","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplant Infectious Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/tid.14319","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/17 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Multidrug-resistant organisms are increasing and are a significant cause of mortality among lung transplant recipients (LTRs). To assist with this issue, novel pharmacotherapies are being developed. This study describes the utilization of a novel antibiotic, cefiderocol (FDC), in LTRs where limited data exists in the current literature. We primarily assessed the clinical indications, duration of therapy, resistance, and adverse effects.

Methods: Conducted as a single-center retrospective review, this study included adult LTRs who received FDC for at least 24 h. Data, extracted from electronic medical records, encompassed patient demographics, transplant history, antimicrobial dosing, adverse effects, bacterial cultures, and outcomes. The research protocol received institutional review board approval.

Results: FDC exhibited effectiveness against multidrug-resistant Pseudomonas aeruginosa, with 26% 30-day mortality and microbiological clearance observed in nine out of 13 cases. Notably, FDC was used in diverse clinical settings, including for prophylaxis, empiric, and targeted treatment.

Conclusion: Further studies are needed to evaluate optimal clinical indications for FDC use in LTRs.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

单个中心肺移植受者对头孢羟氨苄的使用情况。

背景：耐多药生物日益增多，是肺移植受者（LTR）死亡的一个重要原因。为解决这一问题，目前正在开发新型药物疗法。本研究介绍了新型抗生素头孢克洛（FDC）在肺移植受者中的应用情况，目前文献中的数据有限。我们主要评估了临床适应症、疗程、耐药性和不良反应：本研究以单中心回顾性研究的形式进行，纳入了接受 FDC 治疗至少 24 小时的成年 LTR 患者。数据来自电子病历，包括患者人口统计学、移植史、抗菌药物剂量、不良反应、细菌培养和结果。研究方案获得了机构审查委员会的批准：结果：FDC对耐多药性铜绿假单胞菌有效，30天死亡率为26%，13例中有9例观察到微生物清除。值得注意的是，FDC 可用于不同的临床环境，包括预防性治疗、经验性治疗和针对性治疗：结论：需要进一步研究以评估 FDC 用于 LTR 的最佳临床适应症。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Transplant Infectious Disease 医学-传染病学

CiteScore

5.30

自引率

7.70%

发文量

210

审稿时长

4-8 weeks

期刊介绍： Transplant Infectious Disease has been established as a forum for presenting the most current information on the prevention and treatment of infection complicating organ and bone marrow transplantation. The point of view of the journal is that infection and allograft rejection (or graft-versus-host disease) are closely intertwined, and that advances in one area will have immediate consequences on the other. The interaction of the transplant recipient with potential microbial invaders, the impact of immunosuppressive strategies on this interaction, and the effects of cytokines, growth factors, and chemokines liberated during the course of infections, rejection, or graft-versus-host disease are central to the interests and mission of this journal. Transplant Infectious Disease is aimed at disseminating the latest information relevant to the infectious disease complications of transplantation to clinicians and scientists involved in bone marrow, kidney, liver, heart, lung, intestinal, and pancreatic transplantation. The infectious disease consequences and concerns regarding innovative transplant strategies, from novel immunosuppressive agents to xenotransplantation, are very much a concern of this journal. In addition, this journal feels a particular responsibility to inform primary care practitioners in the community, who increasingly are sharing the responsibility for the care of these patients, of the special considerations regarding the prevention and treatment of infection in transplant recipients. As exemplified by the international editorial board, articles are sought throughout the world that address both general issues and those of a more restricted geographic import.